11. Preclinical biodistribution studies are not needed for vaccine products, unless new administration routes, novel adjuvants or novel additives are used (Table 1). 3.6. Compliance to good laboratory practice Preclinical in vitro and in vivo pharmacology (including biodistribution of mRNA therapeutics ...